NOMAD POWER SOLUTIONS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
NOMAD POWER SOLUTIONS, INC. (NMAD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-05-14
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-03-31 was 0.00%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- NOMAD POWER SOLUTIONS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-07 | ||||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | ||||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-09 | ||||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-10 | ||||
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-12 | ||||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-21 | ||||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-10 | ||||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-26 | ||||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-10 | ||||
| 2019-06-30 | 0.00% 10-Q · filed 2019-08-06 | ||||
| 2018-12-31 | 0.00% 10-K · filed 2020-03-25 | ||||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-25 | ||||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-08 | ||||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-02 | ||||
| 2017-03-31 | 0.00% 10-Q · filed 2018-04-27 | ||||
| 2016-12-31 | 0.00% 10-K · filed 2018-03-23 | ||||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-09 | ||||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-04 | ||||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-10 | ||||
| 2015-12-31 | 0.00% 10-K · filed 2017-03-29 | ||||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-04 | ||||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-10 | ||||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-06 | ||||
| 2014-12-31 | 0.00% 10-K · filed 2016-03-28 | ||||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-10 | ||||
| 2014-07-15 | 0.00% 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | 0.00% 10-Q · filed 2015-08-07 | ||||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-13 | ||||
| 2013-12-31 | 0.00% 10-K · filed 2015-03-27 | ||||
| 2013-06-30 | 0.00% 10-Q · filed 2013-08-05 | ||||
| 2013-03-31 | 0.00% 10-Q · filed 2013-05-09 | ||||
| 2012-12-31 | 0.00% 10-K · filed 2013-03-15 | ||||
| 2012-09-30 | 0.00% 10-Q · filed 2012-11-13 | ||||
| 2012-06-30 | 0.00% 10-Q · filed 2013-08-05 | ||||
| 2012-03-31 | 0.00% 10-Q · filed 2013-05-09 | ||||
| 2011-12-31 | 0.00% 10-K · filed 2013-03-15 | ||||
| 2011-06-30 | 0.00% 10-Q · filed 2012-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |